Vivek Ramaswamy has raised over $8.5 million since his announcement of Ohio Governor election bid from the Republican party following his exit from the Department of Government Efficiency. Axios reported that this much money this early in the election cycle with the primary nearly a full year away is record-breaking. For comparison, Axios reported that Gov. Mike DeWine raised $3 million in the first half of 2021 during his reelection campaign. This money does not include any personal financing from Ramaswamy who spent over $30 million of his own money to fund his presidential campaign which he withdrew to support Donald Trump. “Just the beginning of breaking records in Ohio,” Vivek reacted to his fund news.
What is Vivek Ramaswamy’s net worth? What is his source of wealth?
Vivek Ramaswamy’s net worth in 2025 is estimated to be between $800 million and $1.1 billion, with most sources leaning toward the higher end, around $1 billion. His wealth primarily comes from his 7-11% stake in Roivant Sciences, a biotech company he founded in 2014, valued at over $840 million based on SEC filings and campaign disclosures. Additional wealth stems from his stake in Strive Asset Management (worth over $100 million), investments in stocks, bonds, cryptocurrencies, and real estate, including two Ohio homes valued at $2.5 million.
How did Indian-origin Vivek Ramaswamy become so rich?
Born in 1985 to Indian immigrant parents (his father was a General Electric engineer and attorney, his mother a psychiatrist), Ramaswamy grew up in the Cincinnati suburb of Evendale. He attended St. Xavier High School, graduating as valedictorian in 2003. With his early business acumen, Vivek while he was studying biology at Harvard co-founded a business, StudentBusinesses.com, a tech startup that connected budding entrepreneurs with professional resources via the internet. The business was later sold to the Kauffman Foundation, a nonprofit that fosters entrepreneurs and education.After graduating from Harvard, Ramaswamy joined QVT Financial, a New York-based investment advisory firm and hedge fund manager. He also studied law at Yale University in the same batch as JD Vance. His work at QVT involved investing in biotech companies, which led to his interest in the development of new prescription drugs.Ramaswamy founded Roivant in 2014 to buy or license promising drugs that weren’t a priority for their owners. Roivant would then take over the development process for the potential future medicine. The company organized its developing drugs into subsidiary companies that could be spun off into separate ventures or be sold.In 2015, Ramaswamy cashed out a piece of his Roivant stake, accounting for the majority of his nearly $37.1 million in capital gains on his tax return.A potential Alzheimer’s Disease drug, called intepirdine, was the main drug under development at Axovant, a Roivant subsidiary that the company spun off in a 2015 initial public offering. The stock nearly doubled in price on the first day of trading, making the company worth nearly $3 billion.In 2021, Ramaswamy stepped down as CEO and chairman of Roivant as he pursued new ventures. Then he published his best-selling book ‘Woke Inc’
